Anti-Marburg Virus Antibodies with Defined CDR Sequences
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccine and therapeutic options for Marburg virus (MARV) are limited, with no licensed vaccine or effective therapeutic available, and existing antibody-based treatments have shown varying degrees of success, particularly in animal models, highlighting the need for high-affinity antibodies that can protect against MARV infection.
Innovation Solution
Development of a composition comprising specific reactive anti-Marburg immunoglobulins with defined VH and VL complementarity determining regions (CDRs) that are at most 2 amino acids substituted, deleted, or added, which are reactive against MARV strains such as Ci67, Ravn, Musoke, or Angola, and can be administered as a bispecific antibody, scFv, Fab, or diabody, providing protection through pre-exposure or post-exposure prophylaxis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing antibody-based treatments are used for Marburg virus, then some protection is achieved in animal models, but the protection level varies and is insufficient for reliable therapeutic use
Solution Approach 1:
The patent applies parameter changes by optimizing the antibody's binding affinity parameters through selection of specific complementarity determining regions (CDRs) with defined amino acid sequences. The immunoglobulins are engineered with specific VH and VL CDR sequences that maximize binding strength to Marburg virus glycoprotein, thereby improving protection efficacy while maintaining reliability across different virus strains.
Solution Approach 2:
The patent achieves universality by developing immunoglobulins that can protect against multiple Marburg virus strains (Ci67, Ravn, Musoke, Angola) simultaneously. The antibody design targets conserved regions of the viral glycoprotein, enabling a single therapeutic agent to provide broad-spectrum protection across different MARV variants, thereby improving both reliability and adaptability.
2Reliability
If vaccine candidates targeting glycoprotein are developed, then immune response is generated, but protection levels vary between animal models and clinical applications
Solution Approach 1:
The patent applies the extraction principle by isolating and utilizing only the essential protective component - the specific antibody with defined VH and VL CDR sequences - rather than requiring complex vaccine formulations. This extracted antibody therapy provides reliable protection without the variability and complexity associated with whole-virus or subunit vaccines, simplifying the therapeutic approach while maintaining high efficacy.
3Reliability
If high-affinity antibodies are developed for Marburg virus, then protection efficacy is improved, but the complexity of antibody engineering increases
Solution Approach 1:
The patent applies segmentation by dividing the antibody into its functional components - specifically defining the variable heavy (VH) and variable light (VL) chain complementarity determining regions (CDRs). By specifying particular CDR sequences from immunized non-human primates, the patent creates a modular approach to antibody engineering that achieves high affinity and protection efficacy while maintaining manageable structural complexity through defined sequence segments.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The described immunoglobulins demonstrate protective efficacy against MARV infection in non-human primate models, offering significant protection and potential for human use, with the ability to be administered before or after exposure to the virus, providing immediate and sustained protection.
Implementation Method 1
The immunoglobulins are reactive against Marburg virus strains such as Ci67, Ravn, Musoke, or Angola
Data Source
AI summary
Provided here are immunoglobulins and compositions containing one or more of said immunoglobulins reactive to a strain of Marburg virus. The immunoglobulins and compositions comprising said immunoglobulins can be used prophylactically to prevent a Marburg virus infection or to treat a patient that has been exposed to a Marburg virus in order to reduce a symptom.